Quote | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
Last: | $0.0497 |
---|---|
Change Percent: | -76.09% |
Open: | $0.0523 |
Close: | $0.0497 |
High: | $0.06 |
Low: | $0.015 |
Volume: | 48,286 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
2024-06-28 09:34:19 ET More on NLS Pharmaceutics: NLS Pharmaceutics receives Nasdaq staff delisting determination Financial information for NLS Pharmaceutics Read the full article on Seeking Alpha For further details see: NLS Pharmaceutics looks to raise ...
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys...
Message Board Posts | NLS Pharmaceutics Ltd. Warrant (NASDAQ:NLSPW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Warrant Company Name:
NLSPW Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Warrant Website:
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys...
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical re...
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received noti...